story of the week
FDA Approves First Oral Hormone Therapy for Advanced Prostate Cancer
Phase 3 trial data show 96.7 percent of patients who received Orgovyx achieved and maintained castrate levels of testosterone
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.